magnifying glass
logo for Karyopharm Therapeutics

Karyopharm Therapeutics

Get Full Access

Description

XPOVIO is manufactured by Karyopharm Therapeutics, a global, commercial-stage, research-based biotechnology company, and was previously approved by the U.S. FDA... Read More

Headquarters

Headquarters:

85 Wells Ave, Newton Center, Massachusetts, 02459, United States
Phone

Phone:

(617) 658-0600
Website

Website:

xpovio.com
Employees

Employees:

<25
Revenue

Revenue:

<$5 Million
Popular Searches:

XPOVIO

Karyopharm Therapeutics Inc

XPOVIO.com

XPOVIO™

Healthcare Professional

Karyopharm Therapeutics's Org Chart

Tj Randhawa
Tj Randhawa

Chief Executive Officer

PhonePhoneEmailEmail
Edward Johnson
Edward Johnson

Vice President, Pharmacy Services

PhonePhoneEmailEmail

PhonePhoneEmailEmail

PhonePhoneEmailEmail

PhonePhoneEmailEmail
Illustration of an envelope

Karyopharm Therapeutics's Tech Stack

GoDaddy DNS

By

GoDaddy.com

Facebook Analytics

By

Facebook

Microsoft IIS

By

Microsoft

Google Tag Manager

By

Google

OneTrust Cookie Consent

By

OneTrust
See more technologies

Karyopharm Therapeutics News & Media

Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and Myelofibrosis

NEWTON, Mass., July 28, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patients in two new company-sponsored Phase 2 and 1/2 clinical studies evaluating...

Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress

NEWTON, Mass., Feb. 11, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2020. In addition, Karyopharm...

Karyopharm Announces XPOVIO® (selinexor) Receives Regulatory Approval in Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell Lymphoma

NEWTON, Mass., Feb. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its partner Promedico Ltd., a member of the Neopharm Group, has received a principal approval letter...
Subscribe to "Karyopharm Therapeutics" News

Frequently Asked Questions regarding Karyopharm Therapeutics

Where are Karyopharm Therapeutics’s headquarters?

Karyopharm Therapeutics’s headquarters are in 85 Wells Ave, Newton Center, Massachusetts, 02459, United States

What is Karyopharm Therapeutics’s phone number?

Karyopharm Therapeutics’s phone number is (617) 658-0600

What is Karyopharm Therapeutics’s official website?

Karyopharm Therapeutics’s official website is xpovio.com

What is Karyopharm Therapeutics’s Revenue?

Karyopharm Therapeutics’s revenue is <$5 Million

How many employees are working in Karyopharm Therapeutics?

Karyopharm Therapeutics has <25 employees

What is Karyopharm Therapeutics's tech stack?

The technologies that are used by Karyopharm Therapeutics are: Cogent, GoDaddy DNS, Facebook Analytics, Microsoft IIS

Who is Karyopharm Therapeutics's CEO?

Karyopharm Therapeutics's CEO is Tj Randhawa

See more information about Karyopharm Therapeutics

Browse ZoomInfo’s Directories